Susan Hoffstetter, PhD
Women's Health · Saint Louis, MONPI 1326016619
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $36,967 of the $38,860 with a category attached, or 95.1%. Organon accounts for 95.5% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $11,344 and has fallen 80.6% since, to $2,198 in 2025. Among women's health clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 80 payments — averaging $485.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organon$37K
- Scynexis, Inc.$1K
- Lupin Inc.$400
- Astellas Pharma US Inc$81
- AbbVie$32
- Merck$18
What the payments were for
- Consulting fees$4001%
- Speaking & faculty fees$36,96795%
- Travel & lodging$6372%
- Food & beverage$7912%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organon | 73 | $37,104 |
| Scynexis, Inc. | 1 | $1,225 |
| Lupin Inc. | 1 | $400 |
| Astellas Pharma US Inc | 2 | $81 |
| AbbVie | 2 | $32 |
| Merck | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$38,860 in reported general payments places this provider in the 95th percentile of 208 women's health providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 50 | $6,951 |
| Nystatin | 394 | $4,580 |
| Clobetasol Propionate | 27 | $1,871 |
| Gabapentin | 113 | $1,181 |
| Triamcinolone Acetonide | 345 | $1,030 |
| Nystatin-TriamcinoloneNystatin/Triamcinolone Acet | 37 | $946 |
| ValacyclovirValacyclovir Hcl | 19 | $715 |
| Fluocinonide | 11 | $572 |
| Solifenacin Succinate | 12 | $287 |
| NyamycNystatin | 13 | $255 |
| Fluconazole | 60 | $201 |
Paid to pharmacies, not to this prescriber.
Other women's health in Saint Louis
- Nealya Bell-SilvaSaint Louis$107K
- Janice EislebenSaint Louis$16K
- Susan Mitchell-DerenskiSaint Louis$14K
- Amanda SchillySaint Louis$8K
- Kris ScalfSaint Louis$7K
- Savannah HayesSaint Louis$6K
- Kelly BallSaint Louis$4K
- Anna BartonSaint Louis$3K
- Amanda MetzSaint Louis$3K
- Rachel BenderSaint Louis$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.